| Literature DB >> 24225973 |
Michael B Streiff, Paula L Bockenstedt, Spero R Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E Fogerty, Shuwei Gao, Samuel Z Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T Lee, Michael M Millenson, Anne T Neff, Thomas L Ortel, Tanya Siddiqi, Judy L Smith, Gary C Yee, Anaadriana Zakarija, Nicole McMillian, Maoko Naganuma.
Abstract
Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.Entities:
Mesh：
Substances：
Year: 2013 PMID： 24225973 DOI： 10.6004/jnccn.2013.0163
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908